Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Assistance Publique-Hôpitaux De Paris (Aphp) maintains a portfolio with 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 5 distinct examiners, indicating a high degree of individual attention per case. The prosecution spans 3 distinct art units, showing technical diversity within the broader pharmaceutical field. This distribution across 3 distinct art units may require the applicant to adapt to different examination standards and timelines within the office, as each unit may have its own procedural nuances.
The busiest examiner, MCMILLIAN, KARA RENITA, is responsible for 1 pending office action. Because the busiest examiner pending count is 1 and there are 5 distinct examiners for the 5 total actions, every pending matter is currently assigned to a different person. This lack of examiner overlap across the 5 pending office actions means that prosecution strategies must be independently managed for each case. Coordination across the 3 distinct art units is essential to maintain a cohesive intellectual property strategy for the company, as no single examiner has a dominant influence over the active docket.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCMILLIAN, KARA RENITA | 1 | 30.7% | +37.9% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 75.2% | +34.0% |
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
| HIBBERT, CATHERINE S | 1 | 58.9% | +48.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031251 | TG2 INHIBITORS FOR IMPROVING MUCOCILIARY CLEARANCE IN RESPIRATORY DISEASES | HIBBERT, CATHERINE S | 105d overdue |
| 18717719 | USE OF CATECHIN FOR THE TREATMENT OF FGFR-RELATED BONE REPAIR AND BONE FORMATION IMPAIRMENT | MCMILLIAN, KARA RENITA | — |
| 18711519 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS | HEASLEY, MEGHAN CHRISTINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031251 | TG2 INHIBITORS FOR IMPROVING MUCOCILIARY CLEARANCE IN RESPIRATORY DISEASES | HIBBERT, CATHERINE S | 105d overdue |
| 18561797 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY ALVEOLAR PROTEINOSIS RELATED TO MARS MUTATIONS | HERNANDEZ, JACKSON J | 43d |
| 18717719 | USE OF CATECHIN FOR THE TREATMENT OF FGFR-RELATED BONE REPAIR AND BONE FORMATION IMPAIRMENT | MCMILLIAN, KARA RENITA | — |
| 18711519 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS | HEASLEY, MEGHAN CHRISTINE | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717719 | USE OF CATECHIN FOR THE TREATMENT OF FGFR-RELATED BONE REPAIR AND BONE FORMATION IMPAIRMENT | MCMILLIAN, KARA RENITA | — | §103§112Other | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18711519 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS | HEASLEY, MEGHAN CHRISTINE | — | §102§112 | Non-Final OA | — | Pending | May 17, 2024 |
| 18561797 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY ALVEOLAR PROTEINOSIS RELATED TO MARS MUTATIONS | HERNANDEZ, JACKSON J | 1627 | §103 | Final Rejection | 43d | Pending | Nov 17, 2023 |
| 18031251 | TG2 INHIBITORS FOR IMPROVING MUCOCILIARY CLEARANCE IN RESPIRATORY DISEASES | HIBBERT, CATHERINE S | 1658 | §102§112 | Non-Final OA | 105d overdue | Pending | Apr 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial